Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imlifidase desensitization before deceased-donor kidney transplantation in highly sensitized crossmatch-positive patients
NL-OMON55984Phase 3Recruiting
- Sponsor
- Hansa Biopharma
- Start
- Oct 2022
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of efgartigimod alfa in end-stage kidney disease (ESKD) (3 arms), sponsored by Hansa Biopharma. Primary endpoint: 1-year graft failure-free survival. Started Oct 2022; status: recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on NL-OMON55984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55984.